MILLIPLEX^® Human Immuno-Oncology Checkpoint Protein Panel

Luminex is a registered trademark of Luminex Corp

MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany

xMAP is a registered trademark of Luminex Corp

Cross-reactivity between the antibodies and any of the other analytes in this panel is non-detectable or negligible.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

For research use only. Not for use in diagnostic procedures.Label License/Sticker for Assay Product:By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.

For research use only. Not for use in diagnostic procedures.Label License/Sticker for Assay Product:By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.

For research use only. Not for use in diagnostic procedures.Label License/Sticker for Assay Product:By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.

Immune checkpoint proteins are regulators of immune activation and play a key role in maintaining immune homeostasis, preventing autoimmunity, and are involved in cancer immune escape. These immune system molecules demonstrate the ability to act both as agonists (co-stimulatory checkpoint molecules) or antagonists (co-inhibitory checkpoint molecules) of immune response. Immune checkpoint inhibitor drugs targeting inhibitory immune checkpoint proteins, such as CTLA-4 and PD-L1, have demonstrated efficacy in cancer immunotherapy by improving the antitumor immune response and saving lives in the treatment of many malignancies. Immune checkpoint proteins may express on immune cells and/or tumor cells as activating receptors or inhibitory receptors. Many immune checkpoint proteins are also expressed as soluble forms in circulation and in the tumor and tumor microenvironment and are putative biomarkers for immunotherapy in various diseases including cancer.MILLIPLEX^® Human Immuno-Oncology Checkpoint Protein Panel 2 is a 31-plex kit to be used for the simultaneous quantification of any or all of the following analytes in serum, plasma and tissue culture samples: 4-1BBL/TNFSF9, 5′-NT/CD73 (5′-nucleotidase), APRIL (TNFSF13), Arginase-1, B7-H2/ICOSL (Inducible T cell costimulator ligand), B7-H3/CD276, B7-H4/VTCN1 (V-set domain-containing T-cell activation inhibitor 1), B7-H5/VISTA (V-set immunoregulatory receptor), B7-H6 (Natural killer cell cytotoxicity receptor 3 ligand), BAFF/BLyS (TNFSF13B), CD25/IL-2Rα (Interleukin-2 receptor alpha), CD30/TNFRSF8, CD40L (CD40 ligand), CD137/4-1BB (TNFRSF9), CD226/DNAM-1 (DNAX accessory molecule 1), E-Cadherin, FGL1/Hepassocin (Fibrinogen-like protein 1), Galectin-1 (Gal-1), Galectin-3 (Gal-3), Granulysin, Granzyme B, IDO1 (Indoleamine 2,3-dioxygenase 1), MICA (MHC class I polypeptide-related sequence A), MICB (MHC class I polypeptide-related sequence B), Nectin-2 (PVRL2, CD112), Nectin-4 (PVRL4), OX40/CD134 (TNFRSF4), Perforin, PVR/CD155 (Poliovirus receptor cell adhesion molecule), Siglec-7 (Sialic acid-binding Ig-like lectin 7, CD328), Siglec-9 (Sialic acid-binding Ig-like lectin 9, CD329).

Immune checkpoint proteins, such as co-inhibitory molecules (e.g., IDO1, B7-H3) and co-stimulatory signals (e.g., OX40, 4-1BB), orchestrate immune activation and tolerance, playing dual roles in tumor immune evasion and therapeutic response. While inhibitors targeting CTLA-4 and PD-1/PD-L1 have revolutionized cancer treatment, resistance and variable patient outcomes underscore the need to explore novel checkpoints (VISTA, CD73) and tumor microenvironment mediators (Galectin-3, Arginase-1). Emerging research highlights soluble isoforms and lesser-studied membrane proteins as predictive biomarkers and therapeutic targets, driving efforts to decode their spatial, temporal, and combinatorial roles in immune suppression. This multifaceted landscape demands high-dimensional profiling to unravel mechanisms of resistance, optimize combination therapies, and identify sample subsets poised to benefit from next-gen immunotherapies.

96-well plate

Recommended storage for kit components is 2 - 8°C.

MILLIPLEX^® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance. Simultaneously analyze up to 31 analytes in human serum, plasma, and cell culture supernatants.Analytes included: 4-1BBL/TNFSF9, 5′-NT/CD73 (5′-nucleotidase), APRIL (TNFSF13), Arginase-1, B7-H2/ICOSL (Inducible T cell costimulator ligand), B7-H3/CD276, B7-H4/VTCN1 (V-set domain-containing T-cell activation inhibitor 1), B7-H5/VISTA (V-set immunoregulatory receptor), B7-H6 (Natural killer cell cytotoxicity receptor 3 ligand), BAFF/BLyS (TNFSF13B), CD25/IL-2Rα (Interleukin-2 receptor alpha), CD30/TNFRSF8, CD40L (CD40 ligand), CD137/4-1BB (TNFRSF9), CD226/DNAM-1 (DNAX accessory molecule 1), E-Cadherin, FGL1/Hepassocin (Fibrinogen-like protein 1), Galectin-1 (Gal-1), Galectin-3 (Gal-3), Granulysin, Granzyme B, IDO1 (Indoleamine 2,3-dioxygenase 1), MICA (MHC class I polypeptide-related sequence A), MICB (MHC class I polypeptide-related sequence B), Nectin-2 (PVRL2, CD112), Nectin-4 (PVRL4), OX40/CD134 (TNFRSF4), Perforin, PVR/CD155 (Poliovirus receptor cell adhesion molecule), Siglec-7 (Sialic acid-binding Ig-like lectin 7, CD328), Siglec-9 (Sialic acid-binding Ig-like lectin 9, CD329)Assay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.